Financings in Brief: Daltex Medical Sciences
This article was originally published in The Gray Sheet
Executive Summary
Daltex Medical Sciences: Lowers the exercise price and extends the deadline to exercise its class A and B warrants. Effective Oct. 1, 1995, the Fairfield, New Jersey-based firm's class A warrants may be exercised for 25 [cents] a share (down from $3.25) until Dec. 31, 1995 (extended from Sept. 30, 1995). Effective April 1, 1996, class B warrants may be exercised for $3.25 per share (down from $5) until Dec. 31, 1996 (extended from March 31). In September 1994, Daltex extended the expiration dates of the class A and B warrants from Sept. 30, 1994 and March 31, 1995, respectively...
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.